Infertility Drugs

Global Infertility Drugs Market to Reach US$7.0 Billion by 2030

The global market for Infertility Drugs estimated at US$5.2 Billion in the year 2024, is expected to reach US$7.0 Billion by 2030, growing at a CAGR of 5.2% over the analysis period 2024-2030. Hormone-Based Therapy, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$5.3 Billion by the end of the analysis period. Growth in the Other Products segment is estimated at 4.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 8.1% CAGR

The Infertility Drugs market in the U.S. is estimated at US$1.3 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 8.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.1% and 4.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.

Global Infertility Drugs Market - Key Trends & Drivers Summarized

What Are Infertility Drugs and How Do They Support Reproductive Health?

Infertility drugs are medications used to treat reproductive problems in both men and women to increase their chances of conceiving. These drugs generally work by regulating or stimulating ovulation, enhancing sperm production, or correcting hormonal imbalances. In women, common treatments include drugs like Clomiphene citrate, Gonadotropins, and Metformin, which are used to trigger the release of eggs from the ovaries. For men, medications may improve sperm count and quality. The development and use of these drugs are critical as infertility rates have been rising globally, driven by factors such as delayed childbearing, lifestyle changes, and increased prevalence of conditions like polycystic ovary syndrome (PCOS) and endometriosis.

How Are Advances in Medical Research Shaping the Infertility Drugs Market?

The infertility drugs market is continuously shaped by advances in medical research and biotechnology, including the development of more targeted hormone treatments and the introduction of new drug classes. Innovations such as the use of artificial intelligence (AI) to personalize drug protocols based on individual patient responses are enhancing the efficacy and success rates of these treatments. Furthermore, ongoing research into the genetic factors underlying infertility is opening up possibilities for genomic therapies that could correct genetic defects causing reproductive issues. Such advancements not only promise to increase the effectiveness of existing drugs but also help in developing novel therapies with fewer side effects.

What Trends Are Influencing the Demand for Infertility Drugs?

Several trends are currently influencing the demand for infertility drugs. Social trends, including the increasing age of first-time parents, contribute significantly to rising infertility rates, thereby driving the need for effective pharmacological interventions. The growing public awareness and acceptance of fertility treatments, coupled with improvements in healthcare infrastructure, are making these drugs more accessible to a broader population. Moreover, health insurance providers are gradually recognizing the need for comprehensive reproductive health services, including coverage for infertility treatments, which is making these drugs more affordable and further stimulating market growth.

Growth in the Infertility Drugs Market Is Driven by Several Factors

The growth in the infertility drugs market is driven by several factors related to advancements in medical science, changes in socio-economic conditions, and evolving consumer behaviors. Technological progress in drug development and the application of precision medicine are significantly enhancing the effectiveness and reducing the risks associated with infertility treatments. Economic factors, such as increased healthcare spending and the inclusion of fertility treatments in insurance coverage, are making these drugs more accessible and affordable. Additionally, global changes in attitudes towards fertility and an increase in the number of fertility clinics are expanding the consumer base for these drugs. Together, these dynamics are propelling robust growth in the infertility drugs market, reflecting a combination of improved treatment options and broader societal acceptance of fertility issues.

SCOPE OF STUDY:

The report analyzes the Infertility Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product (Hormone-Based Therapy, Other Products)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

• Abbott Laboratories
• AbbVie Inc.
• Allergan Plc
• Bayer AG
• Eli Lilly
• F. Hoffmann-La Roche Ltd
• Ferring Pharmaceuticals AS
• GlaxoSmithKline Plc
• LIVZON Pharmaceutical Group Inc.
• Merck & Co. Inc.
• Merck KGaA
• Novartis AG
• Pfizer Inc.
• Sanofi
• Takeda Pharmaceutical Company Limited
• Zydus Pharmaceuticals

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. Show more